texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Miscellaneous

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Phase:

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Miscellaneous

Location: Texas Oncology-Arlington South

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Arlington North

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Radiation

Indication: Radiation

Location: Texas Oncology-Fort Worth 8th Ave.

Phase:

Title: Retrospective Chart Review: Successful deployment of nurse practitioner-facilitated advance care planning (ACP) in a radiation oncology department View

Renal Cancer

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted T View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Skin Cancer

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Testicular Cancer

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thymomas

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thyroid Cancer

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Uterine Cancer

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Vaginal Cancer

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Arlington North

Indication: Miscellaneous

Location: Texas Oncology-Arlington North

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Arlington South

Indication: Miscellaneous

Location: Texas Oncology-Arlington South

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Bedford

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Fort Worth 12th Ave.

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Phase:

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted T View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Fort Worth 8th Ave.

Indication: Radiation

Location: Texas Oncology-Fort Worth 8th Ave.

Phase:

Title: Retrospective Chart Review: Successful deployment of nurse practitioner-facilitated advance care planning (ACP) in a radiation oncology department View

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Fort Worth Klabzuba

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Grapevine

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

No Phase

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Phase:

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Miscellaneous

Location: Texas Oncology-Arlington South

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Radiation

Location: Texas Oncology-Fort Worth 8th Ave.

Phase:

Title: Retrospective Chart Review: Successful deployment of nurse practitioner-facilitated advance care planning (ACP) in a radiation oncology department View

Indication: Miscellaneous

Location: Texas Oncology-Arlington North

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Phase I

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Phase I/II

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Phase II

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted T View

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Phase III/IV

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase IV

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View